You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 12, September 27, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •HIV/AIDS
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss

After 25 Years Still a Puzzle

W. Keith Henry, MD; Pablo Tebas, MD; H. Clifford Lane, MD

JAMA. 2006;296:1523-1525.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The clinical syndrome of AIDS is due to infection with the human immunodeficiency virus (HIV), which causes a progressive immunodeficiency characterized by the loss of CD4 T lymphocytes coupled with an immunosuppression related to global activation of the immune system. Since the seminal article by Mellors et al in 1996,1 it has been known that as a group, individuals with a higher HIV RNA viral load tend to progress to AIDS and death at a more rapid rate than those with lower viral loads, and that different prognostic information can be derived from the CD4 cell count and the viral load. The conventional wisdom is that the CD4 cell count represents the current state of immune deficiency, whereas the viral load reflects the rate at which the immune system will further deteriorate.2

The report by Rodríguez and colleagues3 in . . . [Full Text of this Article]

Author Affiliations: HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis (Dr Henry); Division of Infectious Diseases, University of Pennsylvania, Philadelphia (Dr Tebas); and Division of Clinical Research and Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Md (Dr Lane).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Predictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection
Benigno Rodríguez, Ajay K. Sethi, Vinay K. Cheruvu, Wilma Mackay, Ronald J. Bosch, Mari Kitahata, Stephen L. Boswell, W. Christopher Mathews, David R. Bangsberg, Jeffrey Martin, Christopher C. Whalen, Scott Sieg, Suhrida Yadavalli, Steven G. Deeks, and Michael M. Lederman
JAMA. 2006;296(12):1498-1506.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry
Kulkarni et al.
Blood 2009;114:2783-2792.
ABSTRACT | FULL TEXT  

Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline
Gottlieb et al.
JAMA 2007;297:805-805.
FULL TEXT  

Predicting CD4-Cell Decline in HIV-Infected Patients
JWatch Infect. Diseases 2006;2006:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.